06:03 AM EDT, 08/06/2026 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured a laboratory services agreement with an undisclosed cancer center in the US for its blood-based biomarker test DiviTum TKa. The deal establishes the framework for the facility to access DiviTum TKa testing services through the Swedish biotechnology company's laboratory in San Diego, US, according to a Thursday release. DiviTum TKa is used to help monitor disease progression in hormone receptor-positive metastatic breast cancer.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.